Literature DB >> 32017694

Male circumcision and prostate cancer: A geographical analysis, meta-analysis, and cost analysis.

Robert S Van Howe1.   

Abstract

INTRODUCTION: Attempts to find an association between male circumcision and prostate cancer risk have produced inconsistent results.
METHODS: Age-standardized prostate cancer incidence, life-expectancy, geographical region, and circumcision prevalence from 188 countries were compared using linear regression analysis. Following a systematic literature review, a meta-analysis was performed on studies meeting inclusion criteria with evaluations of between-study heterogeneity and publication bias. A cost analysis (discounted at 3% and 5% per annum) was performed using the meta-analysis's summary effect and upper confidence interval.
RESULTS: Univariate analysis revealed a trend for a positive association between country-level age-standardized prostate cancer incidence (per 100 000 person-years) and circumcision prevalence (β=0.0887; 95% confidence interval [CI)]-0.0560, +0.233), while multivariate analysis found a significant positive association (β=0.215; 95% CI 0.114, 0.316). Twelve studies were included in meta-analysis. The random-effects summary odds ratio of the risk of being genitally intact was 1.10 (95% CI 0.96, 1.26, between-study heterogeneity χ2 15=27.43; p=0.03; I2=82.8%). There was no evidence of publication bias. Cost analysis found infant circumcision was prohibitively costly, returning only between 1.6¢ and 13.8¢ for each dollar expended.
CONCLUSIONS: Circumcision may be a positive risk factor on geographical analysis, but not in case-case-controlled studies. Circumcision is not economically feasible for preventing prostate cancer.

Entities:  

Year:  2020        PMID: 32017694      PMCID: PMC7337715          DOI: 10.5489/cuaj.6126

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  56 in total

Review 1.  Advanced methods in meta-analysis: multivariate approach and meta-regression.

Authors:  Hans C van Houwelingen; Lidia R Arends; Theo Stijnen
Journal:  Stat Med       Date:  2002-02-28       Impact factor: 2.373

2.  Association of male circumcision with risk of prostate cancer: a meta-analysis.

Authors:  N Pabalan; E Singian; H Jarjanazi; A Paganini-Hill
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-07-28       Impact factor: 5.554

3.  Prophylaxis of cancer of the prostate, penis, and cervix by circumcision.

Authors:  A RAVICH; R A RAVICH
Journal:  N Y State J Med       Date:  1951-06-15

Review 4.  Does male circumcision affect sexual function, sensitivity, or satisfaction?--a systematic review.

Authors:  Brian J Morris; John N Krieger
Journal:  J Sex Med       Date:  2013-08-12       Impact factor: 3.802

5.  An adjustment to the 1997 estimate for new prostate cancer cases.

Authors:  P A Wingo; S Landis; L A Ries
Journal:  CA Cancer J Clin       Date:  1997 Jul-Aug       Impact factor: 508.702

6.  Epidemiology of cancer of the prostate.

Authors:  E L Wynder; K Mabuchi; W F Whitmore
Journal:  Cancer       Date:  1971-08       Impact factor: 6.860

7.  Canadian Urological Association guideline on the care of the normal foreskin and neonatal circumcision in Canadian infants (full version).

Authors:  Sumit Dave; Kourosh Afshar; Luis H Braga; Peter Anderson
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

8.  A case-control study of cancer of the prostate in Somerset and east Devon.

Authors:  P Ewings; C Bowie
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

Review 9.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.

Authors:  Andrew E Grulich; Marina T van Leeuwen; Michael O Falster; Claire M Vajdic
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

10.  Countries with high circumcision prevalence have lower prostate cancer mortality.

Authors:  Mitchell S Wachtel; Shengping Yang; Brian J Morris
Journal:  Asian J Androl       Date:  2016 Jan-Feb       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.